205 related articles for article (PubMed ID: 23528371)
41. Role of single-agent purine analogues in therapy of peripheral T-cell lymphomas.
Dearden CE
Semin Hematol; 2006 Apr; 43(2 Suppl 2):S22-6. PubMed ID: 16549111
[TBL] [Abstract][Full Text] [Related]
42. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors.
Mak V; Hamm J; Chhanabhai M; Shenkier T; Klasa R; Sehn LH; Villa D; Gascoyne RD; Connors JM; Savage KJ
J Clin Oncol; 2013 Jun; 31(16):1970-6. PubMed ID: 23610113
[TBL] [Abstract][Full Text] [Related]
43. Pralatrexate: a novel synthetic antifolate for relapsed or refractory peripheral T-cell lymphoma and other potential uses.
Hui J; Przespo E; Elefante A
J Oncol Pharm Pract; 2012 Jun; 18(2):275-83. PubMed ID: 21956523
[TBL] [Abstract][Full Text] [Related]
44. Peripheral T-cell lymphoma in children and adolescents: a single-institution experience.
Al Mahmoud R; Weitzman S; Schechter T; Ngan B; Abdelhaleem M; Alexander S
J Pediatr Hematol Oncol; 2012 Nov; 34(8):611-6. PubMed ID: 23042011
[TBL] [Abstract][Full Text] [Related]
45. Peripheral T-cell lymphoma.
Foss FM; Zinzani PL; Vose JM; Gascoyne RD; Rosen ST; Tobinai K
Blood; 2011 Jun; 117(25):6756-67. PubMed ID: 21493798
[TBL] [Abstract][Full Text] [Related]
46. T time: Emerging and new therapies for peripheral T-cell lymphoma.
Mina A; Pro B
Blood Rev; 2022 Mar; 52():100889. PubMed ID: 34716031
[TBL] [Abstract][Full Text] [Related]
47. Novel treatment avenues for peripheral T-cell lymphomas.
Hopfinger G; Griessl R; Sifft E; Taylor N; Kenner L; Greil R; Merkel O
Expert Opin Drug Discov; 2012 Dec; 7(12):1149-63. PubMed ID: 22998641
[TBL] [Abstract][Full Text] [Related]
48. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01.
d'Amore F; Relander T; Lauritzsen GF; Jantunen E; Hagberg H; Anderson H; Holte H; Österborg A; Merup M; Brown P; Kuittinen O; Erlanson M; Østenstad B; Fagerli UM; Gadeberg OV; Sundström C; Delabie J; Ralfkiaer E; Vornanen M; Toldbod HE
J Clin Oncol; 2012 Sep; 30(25):3093-9. PubMed ID: 22851556
[TBL] [Abstract][Full Text] [Related]
49. [Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS)].
Kinoshita T
Nihon Rinsho; 2014 Mar; 72(3):512-8. PubMed ID: 24724412
[TBL] [Abstract][Full Text] [Related]
50. Oral fludarabine in combination with doxorubicin and dexamethasone as first-line therapy for nodal peripheral T-cell lymphomas: early results of a prospective multicenter study.
Liu XJ; Guo Y; Fan Y; Gu KS; Cao JN; Wu XH; Zhang J; Li XQ; Wang CF; Hong XN
Cancer Chemother Pharmacol; 2012 Feb; 69(2):387-95. PubMed ID: 21789688
[TBL] [Abstract][Full Text] [Related]
51. MLN8237 ( alisertib ) and its role in peripheral T-cell lymphoma.
Alrifai D; Pettengell R
Expert Opin Investig Drugs; 2014 Dec; 23(12):1731-6. PubMed ID: 25323772
[TBL] [Abstract][Full Text] [Related]
52. Autologous stem cell transplantation with busulfan, cyclophosphamide, and etoposide as an intensifying frontline treatment in patients with peripheral T cell lymphomas: a multicenter retrospective trial.
Ahn JS; Yang DH; Jung SH; Chae YS; Sohn SK; Yhim HY; Kwak JY; Lee SR; Kim YK; Kim HJ; Lee JJ
Ann Hematol; 2013 Jun; 92(6):789-97. PubMed ID: 23358616
[TBL] [Abstract][Full Text] [Related]
53. Therapeutic options in peripheral T cell lymphoma.
Zhang Y; Xu W; Liu H; Li J
J Hematol Oncol; 2016 Apr; 9():37. PubMed ID: 27071634
[TBL] [Abstract][Full Text] [Related]
54. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
55. Novel therapies in peripheral T-cell lymphomas.
O'Leary HM; Savage KJ
Curr Oncol Rep; 2008 Sep; 10(5):404-11. PubMed ID: 18706268
[TBL] [Abstract][Full Text] [Related]
56. High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience.
Rodriguez J; Caballero MD; Gutierrez A; Gandarillas M; Sierra J; Lopez-Guillermo A; Sureda A; Zuazu J; Marin J; Arranz R; Carreras E; Leon A; De Sevilla AF; San Miguel JF; Conde E;
Haematologica; 2003 Dec; 88(12):1372-7. PubMed ID: 14687990
[TBL] [Abstract][Full Text] [Related]
57. CHOEP-21 chemotherapy for newly diagnosed nodal peripheral T-cell lymphomas (PTCLs) in Maharaj Nakorn Chiang Mai Hospital.
Rattarittamrong E; Norasetthada L; Tantiworawit A; Chai-Adisaksopha C; Nawarawong W
J Med Assoc Thai; 2013 Nov; 96(11):1416-22. PubMed ID: 24428090
[TBL] [Abstract][Full Text] [Related]
58. Update: peripheral T-cell lymphomas.
Savage KJ
Curr Hematol Malig Rep; 2011 Dec; 6(4):222-30. PubMed ID: 21953415
[TBL] [Abstract][Full Text] [Related]
59. Update on histone deacetylase inhibitors in peripheral T-cell lymphoma (PTCL).
Lu G; Jin S; Lin S; Gong Y; Zhang L; Yang J; Mou W; Du J
Clin Epigenetics; 2023 Aug; 15(1):124. PubMed ID: 37533111
[TBL] [Abstract][Full Text] [Related]
60. The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas.
Briski R; Feldman AL; Bailey NG; Lim MS; Ristow K; Habermann TM; Macon WR; Inwards DJ; Colgan JP; Nowakowski GS; Kaminski MS; Witzig TE; Ansell SM; Wilcox RA
Blood Cancer J; 2014 May; 4(5):e214. PubMed ID: 24879115
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
